BCRX Stock Analysis: Buy, Sell, or Hold?
BCRX - BioCryst Pharmaceuticals Inc
$8.98
-0.26 (-2.81%)
▼
5d:
-3.85%
30d:
-6.94%
90d:
-1.97%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 5.8/10
Get Alerted When BCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BCRX trading at deep discount. Market pricing in -17.1% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: BCRX trading at deep discount. Market pricing in -17.1% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.77
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$19.10
53.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BCRX is currently trading at $8.98, which is considered oversold relative to its 30-day fair value range of $9.19 to $10.26. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.0) compared to its historical average (15.8). Remarkably, the market is currently pricing in an annual earnings decline of 17.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BCRX is showing support break momentum. The price is currently testing key support at $8.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+133.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BCRX is showing support break momentum. The price is currently testing key support at $8.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.00 (+133.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.19 -
$10.26
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 133.9% below Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$9.19 -
$10.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.93
Resistance Level
$9.91
Current Trend
Support Break
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.98
Wall Street Target
$21.00
(+133.9%)
Revenue Growth (YoY)
7.5%
Profit Margin
-51.7%
Valuation Discount vs History
-17.1% cheaper
PE vs Historical
9.0 vs 15.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.1%
(market-implied from PE analysis)
1-Year Target
$8.08
(-10%)
2-Year Target
$7.27
(-19%)
3-Year Target
$6.55
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→16)
$11.52
(+28%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 51.5%)
$69.96
(+679%)
Base:
(SPY PE: 9.0, Growth: 51.5%)
$30.31
(+238%)
Bear:
(PE: 7.6, Growth: 51.5%)
$25.76
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.0 to 15.8
Stabilization Target:
$15.80
(+75.9%)
PE Expansion Potential:
+75.9%
Share & Embed Analysis
Last updated: August 02, 2026 11:25 PM ET
Data refreshes hourly during market hours. Next update: 12:25 AM
Data refreshes hourly during market hours. Next update: 12:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alane P Barnes
SELL
150000 shares
2026-03-16
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced BCRX Option Strategies
Professional options setups generated by AI based on today's BCRX price and gamma walls.
